Health & Fitness
Health and Fitness
Health and Fitness 
Tue, May 25, 2010
[ Tue, May 25th 2010
] - Market Wire
[ Tue, May 25th 2010
] - Market Wire
[ Tue, May 25th 2010
] - Market Wire
[ Tue, May 25th 2010
] - Market Wire
[ Tue, May 25th 2010
] - Market Wire
[ Tue, May 25th 2010
] - Market Wire
[ Tue, May 25th 2010
] - Market Wire
[ Tue, May 25th 2010
] - Market Wire
[ Tue, May 25th 2010
] - Market Wire
[ Tue, May 25th 2010
] - Market Wire
[ Tue, May 25th 2010
] - Market Wire
[ Tue, May 25th 2010
] - Market Wire
[ Tue, May 25th 2010
] - Market Wire
[ Tue, May 25th 2010
] - Market Wire
[ Tue, May 25th 2010
] - Market Wire
[ Tue, May 25th 2010
] - Market Wire
[ Tue, May 25th 2010
] - Market Wire
[ Tue, May 25th 2010
] - Market Wire
[ Tue, May 25th 2010
] - Market Wire
[ Tue, May 25th 2010
] - Market Wire
[ Tue, May 25th 2010
] - Market Wire
[ Tue, May 25th 2010
] - Market Wire
[ Tue, May 25th 2010
] - Market Wire
[ Tue, May 25th 2010
] - Market Wire
[ Tue, May 25th 2010
] - Market Wire
[ Tue, May 25th 2010
] - Market Wire
[ Tue, May 25th 2010
] - Market Wire
[ Tue, May 25th 2010
] - Market Wire
[ Tue, May 25th 2010
] - Market Wire
[ Tue, May 25th 2010
] - Market Wire
[ Tue, May 25th 2010
] - Market Wire
[ Tue, May 25th 2010
] - Market Wire
Mon, May 24, 2010
[ Mon, May 24th 2010
] - Market Wire
[ Mon, May 24th 2010
] - Market Wire
[ Mon, May 24th 2010
] - Market Wire
[ Mon, May 24th 2010
] - Market Wire
[ Mon, May 24th 2010
] - Market Wire
[ Mon, May 24th 2010
] - Market Wire
[ Mon, May 24th 2010
] - Market Wire
[ Mon, May 24th 2010
] - WOPRAI
[ Mon, May 24th 2010
] - WOPRAI
[ Mon, May 24th 2010
] - WOPRAI
[ Mon, May 24th 2010
] - WOPRAI
[ Mon, May 24th 2010
] - Market Wire
[ Mon, May 24th 2010
] - Market Wire
[ Mon, May 24th 2010
] - Market Wire
[ Mon, May 24th 2010
] - Market Wire
[ Mon, May 24th 2010
] - Market Wire
[ Mon, May 24th 2010
] - Market Wire
[ Mon, May 24th 2010
] - Market Wire
[ Mon, May 24th 2010
] - Market Wire
[ Mon, May 24th 2010
] - Market Wire
[ Mon, May 24th 2010
] - Market Wire
[ Mon, May 24th 2010
] - Market Wire
[ Mon, May 24th 2010
] - Market Wire
[ Mon, May 24th 2010
] - Market Wire
[ Mon, May 24th 2010
] - Market Wire
[ Mon, May 24th 2010
] - Market Wire
[ Mon, May 24th 2010
] - Market Wire
[ Mon, May 24th 2010
] - Market Wire
[ Mon, May 24th 2010
] - Market Wire
[ Mon, May 24th 2010
] - Market Wire
[ Mon, May 24th 2010
] - Market Wire
[ Mon, May 24th 2010
] - Market Wire
[ Mon, May 24th 2010
] - Market Wire
[ Mon, May 24th 2010
] - Market Wire
[ Mon, May 24th 2010
] - Market Wire
[ Mon, May 24th 2010
] - Market Wire
[ Mon, May 24th 2010
] - Market Wire
[ Mon, May 24th 2010
] - Market Wire
[ Mon, May 24th 2010
] - Market Wire
[ Mon, May 24th 2010
] - Market Wire
[ Mon, May 24th 2010
] - Market Wire
[ Mon, May 24th 2010
] - Market Wire
[ Mon, May 24th 2010
] - Market Wire
[ Mon, May 24th 2010
] - Market Wire
[ Mon, May 24th 2010
] - Market Wire
[ Mon, May 24th 2010
] - Market Wire
[ Mon, May 24th 2010
] - Market Wire
[ Mon, May 24th 2010
] - Market Wire
[ Mon, May 24th 2010
] - Market Wire
[ Mon, May 24th 2010
] - Market Wire
[ Mon, May 24th 2010
] - Market Wire
[ Mon, May 24th 2010
] - Market Wire
[ Mon, May 24th 2010
] - Market Wire
[ Mon, May 24th 2010
] - Market Wire
[ Mon, May 24th 2010
] - Market Wire
[ Mon, May 24th 2010
] - Market Wire
[ Mon, May 24th 2010
] - Market Wire
Biogen Idec en Abbott schrijven eerste patint in voor mondiaal fase-3 onderzoek naar behandeling recidief-remitterende multiple
CAMBRIDGE, Mass. & ABBOTT PARK, Ill.--([ BUSINESS WIRE ])--Biogen Idec (NASDAQ: BIIB) en Abbott (NYSE: ABT) maken vandaag bekend dat de eerste patint is ingeschreven voor een wereldwijd fase-3 onderzoek ter evaluatie van de werkzaamheid en veiligheid van daclizumab vergeleken met interferon beta-1a (AVONEX) in patinten met recidief-remitterende multiple sclerose (RRMS), de meest voorkomende vorm van multiple sclerose (MS). Het zogenaamde DECIDE-onderzoek richt zich op een maandelijkse onderhuidse toediening van daclizumab, die zou kunnen leiden tot een nieuwe immunomodulerende aanpak bij de behandeling van MS.
Deze bekendmaking is officieel geldend in de originele brontaal. Vertalingen zijn slechts als leeshulp bedoeld en moeten worden vergeleken met de tekst in de brontaal welke als enige juridische geldigheid beoogt.